Product Inquiry
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| ALXN-1850 | ALXN-1850 | Phase 3 Clinical | Alexion Pharmaceuticals Inc | Hypophosphatasia | Details |
| DS-1211 | DS-1211 | Phase 2 Clinical | Sanford Burnham Prebys Medical Discovery Institute, Daiichi Sankyo Co Ltd | Ossification, Heterotopic; Pseudoxanthoma Elasticum | Details |
| ALXN-1910 | ALXN-1910 | Phase 1 Clinical | Alexion Pharmaceuticals Inc | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | Earliest Brand Name | Earliest Approval Country | Earliest Indication | Earliest Approval Company | Earliest Approval Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Asfotase alfa | sTNALP-FcD10; ALXN-1215; sALP-FcD10; ENB-0040 | Approved | Alexion Pharmaceuticals Inc | Strensiq | Japan | Hypophosphatasia | Alexion Pharmaceuticals Inc | 2015-07-03 | Hypophosphatasia | Details |